Neuron-Specific Enolase in Neuroendocrine Tumors of the Thymus, Bronchus, and Skin

1984 ◽  
Vol 131 (1) ◽  
pp. 184-184
Author(s):  
M.R. Wick ◽  
B.W. Scheithauer ◽  
K. Kovacs
Keyword(s):  
Neuroendocrine Tumors ◽  
Neuron Specific Enolase ◽  
Tumors Of The Thymus

Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors

Cancer ◽  
1999 ◽  
Vol 86 (5) ◽  
pp. 858-865 ◽  
Author(s):  
Emilio Bajetta ◽  
Leonardo Ferrari ◽  
Antonia Martinetti ◽  
Luigi Celio ◽  
Giuseppe Procopio ◽  
...  
Keyword(s):  
Acetic Acid ◽  
Carcinoembryonic Antigen ◽  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
Neuron Specific Enolase

Current aspects of diagnosis and treatment of patients with neuroendocrine tumors

2021 ◽  
Vol 23 (3) ◽  
pp. 83-92
Author(s):  
Maxim V. Lysanyuk ◽  
Pavel N. Romashchenko ◽  
Nicolay A. Maistrenko
Keyword(s):  
Gastrointestinal Tract ◽  
Neuroendocrine Tumors ◽  
Survival Rates ◽  
Neuron Specific Enolase ◽  
Treatment Method ◽  
Pancreatic Tumors ◽  
Arterial Phase ◽  
Computed Tomographic ◽  
Positron Emission ◽  
Degree Of Malignancy

The article presents modern possibilities and existing problematic aspects of the choice of therapeutic and diagnostic tactics in patients with neuroendocrine tumors of the gastrointestinal tract and pancreas are presented. The asymptomatic course of neuroendocrine tumors of the gastrointestinal tract and pancreas was established in 18.5% and 24.6% of cases, respectively. Carcinoid syndrome was detected in 12.9%. The sensitivity rates of chromogranin A and neuron-specific enolase in the diagnosis of tumors were 54% and 13%, respectively. The levels of cancer-embryonic antigen in G-1/G-2 and G-3 tumors were 5 ng/ml and 8.9 ng/ml, respectively (p 0.001). A pathognomonic sign of neuroendocrine tumors of the small intestine is a mesentery tumor conglomerate, and the sensitivity rates of computed tomography and positron emission tomography with 68Ga to detect this sign were 92.3% and 92.9%, respectively (p 0.05). The computed tomographic density of neuroendocrine pancreatic tumors G-1/G-2 in the arterial phase was 112.1 40.2 HU and that of G-3 tumors was 54.0 10.4 HU (p = 0.025). Surgical treatment was performed in 259 (79.7%) patients. Postoperative complications that developed in localized and locally distributed neuroendocrine tumors of the gastrointestinal tract and of the pancreas were found in 3.5% and 8.8%, and in 58.1% and 40% of the cases, respectively, and those of generalized tumors were noted in 20%. The tumor-specific 5-year survival rates of patients with localized neuroendocrine tumors of the gastrointestinal tract and pancreas were 92.5% and 94.4%, those with locally distributed tumors had 66.8% and 77.8%, and those with generalized tumors had 51.8% and 47.1%, respectively. In patients with generalized tumors, the 5-year survival rates after cytoreduction and removal of the primary tumor were 88.2% and 64.6%, respectively (p = 0.097), and the rate after drug therapy was 28.8% (p 0.001). The prognosis of the 5-year survival of patients is determined by the degree of malignancy and tumor localization, treatment method, and patient age. In general, neuroendocrine tumors are a heterogeneous group of neoplasms that require a multidisciplinary approach to diagnosis and choice of therapeutic strategies.

Computed tomography characterization of neuroendocrine tumors of the thymus can aid identification and treatment

2013 ◽  
Vol 54 (2) ◽  
pp. 175-180 ◽  
Author(s):  
Hui Li ◽  
De-ling Wang ◽  
Xue-wen Liu ◽  
Zhi-jun Geng ◽  
Chuan-Miao Xie
Keyword(s):  
Computed Tomography ◽  
Neuroendocrine Tumors ◽  
Tumors Of The Thymus

scholarly journals Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs

2018 ◽  
Vol 7 (1) ◽  
pp. 169-178 ◽  
Author(s):  
Yang Lv ◽  
Xu Han ◽  
Chunyan Zhang ◽  
Yuan Fang ◽  
Ning Pu ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Statistical Significance ◽  
Neuron Specific Enolase ◽  
Tumor Grade ◽  
Clinical Value ◽  
Serum Samples ◽  
Individual Values ◽  
Predictive Values ◽  
Combined Test ◽  
The Mean

Purpose Chromogranin A (CgA) and neuron-specific enolase (NSE) are important markers for neuroendocrine tumors; however, the clinical value of combining these markers has not been well studied. In this study, we investigated the utility of each marker individually and in combination for patients with nonfunctional pancreatic neuroendocrine tumors (NF-pNETs). Patients and Methods In this study, NF-pNET patients and controls were recruited from December 2011 to March 2016; 784 serum samples from peripheral vein were collected. The clinical characteristics and biomarker values of all the individuals were recorded and analyzed. Tumor burdens were calculated by CT/MRI scan. Receiver-operating characteristic curves were constructed to assess the diagnostic predictive values; sensitivity and specificity were calculated to determine the cut-off value. Therapeutic responses reflected on the changes of the biomarkers’ concentration were assessed by the RECIST criterion. Clinical relations between the prognosis and the biomarker values were also analyzed. Statistical significance was defined as P value less than 0.05. Results Among the 167 NF-pNETs patients, 82 were males (49.1%) and the mean age was 50.0 (17.4). The mean CgA values of G1, G2 and G3 NF-pNENs were 75, 121 and 134 μg/L (P < 0.05), respectively. In NF-pNETs, CgA correlated with the WHO tumor grade (WHO G1 vs G2, P < 0.05); the linear regression relationships were found between the tumor burdens (both in pancreas and liver) and CgA concentration (P < 0.001); changes in CgA and NSE concentrations also reflect treatment response (P < 0.001). Conclusion CgA and NSE are important diagnostic and follow-up markers in patients with NF-pNETs. The combined monitoring of CgA and NSE possesses more accuracy than individual values of CgA and NSE at predicting prognosis and disease progression.

scholarly journals A Rare Case of Giant Neuroendocrine Tumor of the Thymus Treated with EN Bloc Resection

2019 ◽  
Vol 4 (02) ◽  
Author(s):  
João Isidro Fracasso ◽  
Antônio Benincá Albuquerque ◽  
André Luca Boeira Rovani ◽  
Larissa Maroni ◽  
Guilherme Baroni De Macedo ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Epigastric Pain ◽  
Neuroendocrine Differentiation ◽  
En Bloc Resection ◽  
Anterior Mediastinum ◽  
Bloc Resection ◽  
The Body ◽  
En Bloc ◽  
Tumors Of The Thymus

Neuroendocrine tumors (NETs) are epithelial neoplasms with predominant neuroendocrine differentiation that arise in most organs of the body. Neuroendocrine tumors of the thymus (tNET) and mediastinum are very uncommon. We report the case of a 49-year-old male patient with neuroendocrine tumor of the thymus, superiorly in the anterior mediastinum, asymptomatic of the respiratory tract presenting with epigastric pain, treated with the lesion's surgical resection en bloc associated with radiotherapy and chemotherapy.

Neuron-Specific Enolase in Non-Neoplastic Lung Diseases, a Marker of Hypoxemia?

1998 ◽  
Vol 13 (3) ◽  
pp. 150-153 ◽  
Author(s):  
M. Szturmowicz ◽  
J. Burakowski ◽  
W. Tomkowski ◽  
A. Sakowicz ◽  
S. Filipecki
Keyword(s):  
Mechanical Ventilation ◽  
Respiratory Failure ◽  
Neuroendocrine Tumors ◽  
Lung Diseases ◽  
Elevated Serum ◽  
Neuron Specific Enolase ◽  
Glycolytic Enzyme ◽  
The Other ◽  
Frequent Event

Neuron-specific enolase (NSE) is a glycolytic enzyme localized within neuronal and neuroendocrine tissues. Serum NSE is widely used as a marker of neuroendocrine tumors. Moderate serum NSE elevation has been reported in some patients with benign lung diseases. We decided to investigate whether the elevation of serum NSE in non-neoplastic lung diseases is connected with hypoxemia and to what extent the recovery of sufficient ventilation with a respirator may influence NSE concentrations. Serum NSE was estimated by means of radioimmunoassay in 83 patients with various non-neoplastic lung diseases. Serum NSE exceeding 12.5 μg/L was significantly more frequent in patients with marked hypoxemia (PaO2<6.67 kPa; p=0.03) than in others. The median NSE value in the group of patients without respiratory failure (Ro) was 7.2 μg/L (10% >12.5 μg/L), in the group of patients with respiratory failure not requiring mechanical ventilation (Rf) it was 8.5 μg/L (24%>12.5 μg/L), and in the group of patients with respiratory failure requiring mechanical ventilation (Rfv) 13.1 μg/L (60%>12.5 μg/L). The differences between the Rfv group and the other two groups (Rf and Ro) were significant (p=0.049 and p=0.0004, respectively). During successful mechanical ventilation elevated serum NSE decreased to values below the cutoff in 8/10 patients. We conclude that serum NSE elevation is a frequent event in patients with terminal hypoxemia in the course of benign lung diseases. Normalization of serum NSE is observed in the majority of patients during the first week of mechanical ventilation.

Sign in / Sign up

Export Citation Format

Share Document